Cover: Commentary


Liquid Biopsy for Average-Risk Colorectal Cancer Screening

Published in: Clinical Gastroenterology and Hepatology (2024). DOI: 10.1016/j.cgh.2024.01.034

Posted on Mar 28, 2024

by David A. Lieberman, Aasma Shaukat, Folasade P. May, John M. Carethers, Iris Lansdorp-Vogelaar, Uri Ladabaum, Timothy R. Church, Anjelica Davis, Chyke A. Doubeni, John M. Inadomi, et al.

Despite well-known benefits and clear evidence of programmatic effectiveness in the average-risk population, colorectal cancer (CRC) screening in the United States remains underutilized. Only 60% to 65% of age-eligible individuals are up to date with screening. Emerging blood tests (liquid biopsies [LBs]) detecting circulating nucleotides such as cell-free DNA and/or metabolic products associated with CRC and its precursors could help expand screening. Introduction of new noninvasive screening tests could mitigate disparities, although the high cost could widen disparities.

Research conducted by

This report is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.